Lowering NLRP3 levels, demonstrated in numerous studies to mitigate renal inflammation and improve DKD, is currently critical for therapeutic intervention targeting the TXNIP/NLRP3/caspase-1/GSDMD pathway. Here, TXNIP is linked to diabetic kidney disease.